Biomarker Detection for Anti-TNF Treatment Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for rheumatic diseases, particularly those using anti-TNFα treatments, lack effective biomarkers to predict treatment outcomes, leading to unnecessary costs and inefficiencies as approximately 30% of patients do not respond to the treatment.
Innovation Solution
A method and diagnostic kit that detect immunoglobulins against specific biomarker proteins, such as RAB11B, PPP2R1A, KPNB1, COG4, and FDFT1, in bodily fluids to categorize patients as responders or non-responders before, during, and after anti-TNFα treatment, enabling personalized treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNFα treatment is administered to all rheumatic disease patients, then treatment coverage is maximized, but 30% of patients are non-responders leading to wasted resources and unnecessary costs
Solution Approach 1:
The patent applies preliminary action by detecting immunoglobulins against specific biomarker proteins (RAB11B, PPP2R1A, KPNB1, COG4, FDFT1) before initiating anti-TNFα treatment to predict treatment response. This pre-screening allows clinicians to identify likely responders and non-responders in advance, avoiding unnecessary treatments for predicted non-responders and thereby reducing wasted treatment costs while maintaining high treatment effectiveness for appropriate patients
2Measurement precision
If biomarker detection is performed to predict treatment response, then treatment outcomes can be optimized, but the diagnostic process becomes more complex
Solution Approach 1:
The patent applies segmentation by dividing the complex diagnostic process into detection of specific, discrete biomarker proteins (RAB11B, PPP2R1A, KPNB1, COG4, FDFT1) using targeted immunoglobulin detection. Rather than attempting to measure all possible treatment response indicators, the invention segments the problem into a focused panel of key biomarkers, achieving high prediction accuracy while keeping the diagnostic approach manageable and clinically feasible
Solution Approach 2:
The patent applies universality by developing a multi-functional diagnostic kit that can detect multiple different immunoglobulins against various biomarker proteins using a single integrated system. This universal diagnostic platform can assess treatment response prediction across different rheumatic disease conditions and different anti-TNFα agents, reducing the need for multiple separate tests while maintaining high measurement precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the prediction of treatment outcomes, reducing unnecessary treatments and costs by accurately identifying non-responders before initiating therapy, thereby optimizing treatment strategies for patients with rheumatic diseases.
Implementation Method 1
a method and diagnostic kit that detect immunoglobulins against specific biomarker proteins, such as RAB11B, PPP2R1A, KPNB1, COG4, and FDFT1, in bodily fluids
Data Source
AI summary
The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumor necrosis factor alpha (TNFα or TNF) treatment to assess the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or more biomarker proteins in a bodily fluid or an excrement of said patient, and sorting the individual into one of two categories based on detection of said immunoglobulin(s), wherein individuals are classified as NON-responder or responder. The invention refers to diagnostic kits comprising said one or more biomarker proteins and the use of these kits for assessing the responsiveness to an anti-TNF treatment of an individual who is to be subjected to or is being subjected to an anti-TNFα treatment.